By Dr. Aakash Desai Mayo Clinic KEYNOTE-789: No Significant Efficacy Benefit with Addition of Pembrolizumab to Chemotherapy in TKI-Resistant, EGFR-Mutated Metastatic Nonsquamous NSCLC Key Points: The KEYNOTE-789 trial did not
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 18, 2024, the U.S. Food and Drug Administration granted approval to a potent oral ALK (anaplastic lymphoma kinase) tyrosine kinase inhibitor – Alectinib (Alecensa,
More
Presented by: Joel W Neal, MD. PhD Covered by: Ivy Riano, M.D., Research Chief Fellow, Hematology and Oncology Unit, Dartmouth Cancer Center, Lebanon, NH. Dr. Joel Neal, Associate Professor of Medicine
More
Presented by: Millie Das, MD Covered by: Ivy Riano, M.D., Research Chief Fellow, Hematology and Oncology Unit, Dartmouth Cancer Center, Lebanon, NH. Dr. Millie Das, Chief of Oncology at the Palo
More
Presented by: Alex A. Adjei, MD, PhD, FACP Covered by: Ivy Riano, M.D., Research Chief Fellow, Hematology and Oncology Unit, Dartmouth Cancer Center, Lebanon, NH. Dr. Alex A. Adjei, chair of
More
By Dr. Lei Deng University of Washington & Fred Hutch Watch Dr. Lei Deng’s overview of the KEYNOTE-671 and NADIM II trials, with important implications for non small
More
By Dr. Anish Shah Bronx-Lebanon Hospital On August 9, 2023, the U.S. Food and Drug Administration granted regular approval to pralsetinib for adult patients with metastatic non-small cell lung cancer (NSCLC)
More
By Dr. Aakash Desai Mayo Clinic KEYNOTE-789: No Significant Efficacy Benefit with Addition of Pembrolizumab to Chemotherapy in TKI-Resistant, EGFR-Mutated Metastatic Nonsquamous NSCLC Key Points: The KEYNOTE-789 trial did not
More
Author: Lei Deng, MD Roswell Park Comprehensive Cancer Center Live report from ASCO23, Chicago, IL June 6, 2023 LBA9005 Tumor Treating Field (TTFields) therapy with standard of care (SOC) in
More
Author: Lei Deng, MD Roswell Park Comprehensive Cancer Center Live report from ASCO23, Chicago, IL June 6, 2023 9002 Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations:
More
By Dr. Dipesh Uprety Karmanos Cancer Institute Four cycles of cisplatin-based adjuvant chemotherapy after surgical resection have remained the standard of care for patients with early-stage resectable non-small cell lung cancer
More